Amarin Receives Nasdaq Notification Related to Late Filing of 2008 Annual Report on Form 20-F

DUBLIN--(Business Wire)--
Amarin Corporation plc (NASDAQ: AMRN) announced today that on July 6, 2009, the
Company received a written notification from the Nasdaq Stock Market stating
that it is not in compliance with the filing requirements for continued listing
under Nasdaq Marketplace Rule 5250(c)(1). The Nasdaq notification, which the
Company expected, was issued in accordance with standard Nasdaq procedures due
to the delayed filing of the Company's Annual Report on Form 20-F for the year
ended December 31, 2008 with the U.S. Securities and Exchange Commission. The
Nasdaq notification has no effect on the listing of Amarin`s American Depository
Shares ("ADSs") on Nasdaq at this time, and its ADSs will continue to trade on
the Nasdaq Capital Market under the symbol "AMRN".

As announced on July 1, 2009, Amarin has delayed the filing of its Form 20-F for
the year ended December 31, 2008, as it was unable to comply with the filing
date of June 30, 2009 without unreasonable effort or expense as a result of the
time and attention devoted by Amarin`s management to securing bridge financing
and conducting ongoing discussions with potential investors for longer term
financing. In this regard, the Company also announced today, July 7, 2009, in a
separate press release, that it has signed a non-binding term sheet for a
private placement of up to $55 million. The Company intends to complete these
discussions as soon as possible and file the Annual Report on Form 20-F for the
year ended December 31, 2008 as soon as possible thereafter.

Nasdaq has provided the Company until September 4, 2009 to file its Form 20-F or
submit a plan to regain compliance. If a plan of compliance is submitted, Nasdaq
will review that submission and if it determines that the plan is acceptable,
the Company will have until December 28, 2009 to regain compliance. If Nasdaq
determines that the plan is not acceptable, the Company may appeal such
determination to a Listing Qualifications Panel. Amarin intends to file its
Annual Report on Form 20-F for the year ended December 31, 2008 before September
4, 2009 to regain compliance with Nasdaq's filing requirements for continued
listing.

About Amarin

Amarin is a late-stage biopharmaceutical company with a focus on cardiovascular
disease. The Company`s lead product candidate is AMR101, a prescription grade
Omega-3 fatty acid comprising not less than 96% ultra-pure ethyl
eicosapentaenoic acid (EPA), which is entering Phase 3 clinical trials for the
treatment of hypertriglyceridemia under a Special Protocol Assessment (SPA)
agreement with the U.S. Food and Drug Administration (FDA). Amarin recently
established its research and development headquarters in Mystic, Connecticut
with an experienced research and development team. Amarin`s programs capitalize
on its lipid science expertise and the known therapeutic benefits of Omega-3
fatty acids in treating cardiovascular disease. The pipeline also includes
proprietary next-generation lipid candidates, currently at preclinical stages of
development.

Amarin has a range of clinical and preclinical stage compounds to treat central
nervous system (CNS) disorders, including Huntington`s disease, myasthenia
gravis, Parkinson`s disease and epilepsy, all of which are available for
partnering.Amarin is listed in the U.S. on the NASDAQ Capital Market ("AMRN").
For more information please visit www.amarincorp.com.

Disclosure Notice

The information contained in this document is as of July 7, 2009. Amarin assumes
no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's products in
development that involve substantial risks and uncertainties. You can identify
these statements by the fact that they use words such as "will", "anticipate",
"estimate", "expect", "project", "forecast", "intend", "plan", "believe" and
other words and terms of similar meaning in connection with any discussion of
future operating or financial performance or events. Among the factors that
could cause actual results to differ materially from those described or
projected herein are the following: Amarin's ability to maintain sufficient cash
and other liquid resources to meet its operating and debt service requirements;
growth in costs and expenses; and risks relating to the Company's ability to
maintain its Nasdaq listing. A further list and description of these risks,
uncertainties and other matters can be found in Amarin's Form 20-F for the
fiscal year ended December 31, 2007, filed with the SEC on May 19, 2008 and
Amarin`s Form 20-F/A for the fiscal year ended December 31, 2007 filed with the
SEC on September 24, 2008.

Amarin
+353 (0)1 669 9020
Thomas Lynch, Chairman and Chief Executive Officer
or
Alan Cooke, President and Chief Operating Officer
or
Darren Cunningham, EVP Strategic Development and Investor Relations
investor.relations@amarincorp.com

Copyright Business Wire 2009